“Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of Combined Epalrestat- Dapagliflozin Regimen” (2024)
Iranian Journal of Kidney Diseases
, 18(05). doi:
10.52547/ax1vqh41
.